Find Surufatinib manufacturers, exporters & distributors on PharmaCompass

Surufatinib

Surufatinib

Synopsis, Chemistry

DEVELOPMENTS

16 Drug(s) in Development

16 Drug(s) in Development

INTERMEDIATES

1 Suppliers

1 Suppliers

DIGITAL CONTENT

21 News

21 News

Product Search

API SUPPLIERS

API Suppliers

US DMFs Filed

CEP/COS Certifications

JDMFs Filed

Other Certificates

Other Suppliers

API REF. PRICE (USD / KG)

API Market Place

INTERMEDIATES

DOSSIERS // FDF

USA (Orange Book)

Europe

Canada

Australia

South Africa

Uploaded Dossiers

GLOBAL SALES (USD Million)

U.S. Medicaid

Annual Reports

FDF Market Place

EXCIPIENTS

PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

USFDA Exclusivities

DIGITAL CONTENT

Blog #PharmaFlow

News

REF STANDARD

EDQM

USP

Other Listed Suppliers

SERVICES

Also known as: 1308672-74-3, Surufatinib, N-(2-(dimethylamino)ethyl)-1-(3-((4-((2-methyl-1h-indol-5-yl)oxy)pyrimidin-2-yl)amino)phenyl)methanesulfonamide, Hmpl-012, Kdr-in-1, 1816307-67-1

Molecular Formula

C₂₄H₂₈N₆O₃S

Molecular Weight

480.6 g/mol

InChI Key

TTZSNFLLYPYKIL-UHFFFAOYSA-N

FDA UNII

B2K5L1L8S9

Sulfatinib is an orally bioavailable, small molecule inhibitor of vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3, and the fibroblast growth factor receptor type 1 (FGFR1), with potential antineoplastic and anti-angiogenic activities. Upon oral administration, sulfatinib binds to and inhibits VEGFRs and FGFR1 thereby inhibiting VEGFR- and FGFR1-mediated signal transduction pathways. This leads to a reduction of angiogenesis and tumor cell proliferation in VEGFR/FGFR1-overexpressing tumor cells. Expression of VEGFRs and FGFR1 may be upregulated in a variety of tumor cell types.

1 2D Structure

Surufatinib

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

N-[2-(dimethylamino)ethyl]-1-[3-[[4-[(2-methyl-1H-indol-5-yl)oxy]pyrimidin-2-yl]amino]phenyl]methanesulfonamide

2.1.2 InChI

InChI=1S/C24H28N6O3S/c1-17-13-19-15-21(7-8-22(19)27-17)33-23-9-10-25-24(29-23)28-20-6-4-5-18(14-20)16-34(31,32)26-11-12-30(2)3/h4-10,13-15,26-27H,11-12,16H2,1-3H3,(H,25,28,29)

2.1.3 InChI Key

TTZSNFLLYPYKIL-UHFFFAOYSA-N

2.1.4 Canonical SMILES

CC1=CC2=C(N1)C=CC(=C2)OC3=NC(=NC=C3)NC4=CC=CC(=C4)CS(=O)(=O)NCCN(C)C

2.2 Other Identifiers

2.2.1 UNII

B2K5L1L8S9

2.3 Synonyms

2.3.1 MeSH Synonyms

1. N-(2-(dimethylamino)ethyl)-1-(3-((4-((2-methyl-1h-indol-5-yl)oxy)pyrimidin-2-yl)amino)phenyl)methanesulfonamide

2. Surufatinib

2.3.2 Depositor-Supplied Synonyms

1. 1308672-74-3

2. Surufatinib

3. N-(2-(dimethylamino)ethyl)-1-(3-((4-((2-methyl-1h-indol-5-yl)oxy)pyrimidin-2-yl)amino)phenyl)methanesulfonamide

4. Hmpl-012

5. Kdr-in-1

6. 1816307-67-1

7. Hmpl012

8. Surufatinib [inn]

9. Surufatinib [usan]

10. B2k5l1l8s9

11. N-[2-(dimethylamino)ethyl]-1-[3-[[4-[(2-methyl-1h-indol-5-yl)oxy]pyrimidin-2-yl]amino]phenyl]methanesulfonamide

12. Benzenemethanesulfonamide, N-(2-(dimethylamino)ethyl)-3-((4-((2-methyl-1h-indol-5-yl)oxy)-2-pyrimidinyl)amino)-

13. Benzenemethanesulfonamide, N-[2-(dimethylamino)ethyl]-3-[[4-[(2-methyl-1h-indol-5-yl)oxy]-2-pyrimidinyl]amino]-

14. Sulanda

15. N-[2-(dimethylamino)ethyl]-1-[3-({4-[(2-methyl-1h-indol-5-yl)oxy]pyrimidin-2-yl}amino)phenyl]methanesulfonamide

16. Sulfatinib [who-dd]

17. Sulfatinib; Hmpl-012

18. Unii-b2k5l1l8s9

19. Surufatinib [who-dd]

20. Gtpl9769

21. Schembl1822601

22. Chembl4297190

23. Bcp14757

24. Ex-a2524

25. Nsc797937

26. Who 10349

27. Akos030632837

28. Zinc117218067

29. Cs-5949

30. Db15106

31. Nsc-797937

32. Ac-35852

33. As-74954

34. Hmpl-012;hmpl 012;hmpl012

35. Hy-12297

36. Vegfr2 Inhibitor [wo2011060746]

37. D71057

38. A926546

39. N-(2-(dimethylamino) Ethyl)-1-(3-((4-((2-methyl-1h-indol-5-yl)oxy)pyrimidin-2-yl)amino)phenyl)methanesulfonamide

40. N-(2-(dimethylamino) Ethyl)-1-(3-((4-(2-methyl-1h-indol-5-yloxy) Pyrimidin-2-yl) Amino) Phenyl) Methanesulfonamide

2.4 Create Date

2011-06-06

3 Chemical and Physical Properties

Molecular Formula	C₂₄H₂₈N₆O₃S
Molecular Weight	480.6 g/mol
XLogP3	3.4
Hydrogen Bond Donor Count	3
Hydrogen Bond Acceptor Count	8
Rotatable Bond Count	10
Exact Mass	480.19435995 g/mol
Monoisotopic Mass	480.19435995 g/mol
Topological Polar Surface Area	121 Å²
Heavy Atom Count	34
Formal Charge	0
Complexity	733
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

4 Drug and Medication Information

4.1 Drug Indication

Treatment of all conditions included in the category of malignant neoplasms (except central nervous system tumours, haematopoietic and lymphoid tissue neoplasms), Treatment of malignant neoplasms of haematopoietic and lymphoid tissue